A novel LRRK2 mutation in a mainland Chinese patient with familial Parkinson's disease

Neuroscience Letters

Volumn 468, Issue 3, 2010, Pages 198-201

  Wang, Lei ^a   Guo, Ji feng ^a,c   Nie, Li luo ^a   Xu, Qian ^a   Zuo, Xing ^a   Sun, Qi ying ^a   Yan, Xin xiang ^a,c   Tang, Bei sha ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b National Laboratory of Medical Genetics of China   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Familial Parkinson's disease; LRRK2; Mutations

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PRAMIPEXOLE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DYSKINESIA; EXON; FAMILIAL DISEASE; FEMALE; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; INTRON; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROLOGIC EXAMINATION; NUCLEOTIDE SEQUENCE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; TREMOR;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES;

EID: 72249109362     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.10.080     Document Type: Article

References (25)

1. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
2. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
3. Lautier C., Goldwurm S., Durr A., Giovannone B., Tsiaras W.G., Pezzoli G., Brice A., and Smith R.J. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am. J. Hum. Genet. 82 (2008) 822-833
4. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Martí-Massó J.F., Pérez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
5. Healy D.G., Abou-Sleiman P.M., Casas J.P., Ahmadi K.R., Lynch T., Gandhi S., Muqit M.M., Foltynie T., Barker R., Bhatia K.P., Quinn N.P., Lees A.J., Gibson J.M., Holton J.L., Revesz T., Goldstein D.B., and Wood N.W. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 59 (2006) 627-633
6. Simon-Sanchez J., and Singleton A.B. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet. 17 (2008) 1988-1993
7. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
8. Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G., Sampaio C., Meco G., Barbosa E., Oostra B.A., and Bonifati V. Italian Parkinson Genetics Network, a frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
9. Lesage S., Leclere L., Lohmann E., Borg M., Ruberg M., Dürr A., and Brice A. French Parkinson's Disease Genetics Study Group, frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease. Neurodegener. Dis. 4 (2007) 195-198
10. Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M., Leutenegger A.L., Guimaraes J., Bonnet A.M., Agid Y., Dürr A., and Brice A. French Parkinson's Disease Genetics Study Group, G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58 (2005) 784-787
11. Ishihara L., Gibson R.A., Warren L., Amouri R., Lyons K., Wielinski C., Hunter C., Swartz J.E., Elango R., Akkari P.A., Leppert D., Surh L., Reeves K.H., Thomas S., Ragone L., Hattori N., Pahwa R., Jankovic J., Nance M., Freeman A., Gouider-Khouja N., Kefi M., Zouari M., Ben Sassi S., Ben Yahmed S., El Euch-Fayeche G., Middleton L., Burn D.J., Watts R.L., and Hentati F. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov. Disord. 22 (2007) 55-61
12. Orr-Urtreger A., Shifrin C., Rozovski U., Rosner S., Bercovich D., Gurevich T., Yagev-More H., Bar-Shira A., and Giladi N. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?. Neurology 69 (2007) 1595-1602
13. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
14. Lin C.H., Tzen K.Y., Yu C.Y., Tai C.H., Farrer M.J., and Wu R.M. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. J. Biomed. Sci. 15 (2008) 661-667
15. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., and Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57 (2005) 918-921
16. Tomiyama H., Li Y., Funayama M., Hasegawa K., Yoshino H., Kubo S., Sato K., Hattori T., Lu C.S., Inzelberg R., Djaldetti R., Melamed E., Amouri R., Gouider-Khouja N., Hentati F., Hatano Y., Wang M., Imamichi Y., Mizoguchi K., Miyajima H., Obata F., Toda T., Farrer M.J., Mizuno Y., and Hattori N. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov. Disord. 21 (2006) 1102-1108
17. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992) 181-184
18. Berg D., Schweitzer K., Leitner P., Zimprich A., Lichtner P., Belcredi P., Brussel T., Schulte C., Maass S., and Nagele T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128 (2005) 3000-3011
19. Covy J.P., Yuan W., Waxman E.A., Hurtig H.I., Van Deerlin V.M., and Giasson B.I. Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov. Disord. 24 (2009) 32-39
20. Di Fonzo A., Wu-Chou Y.H., Lu C.S., van Doeselaar M., Simons E.J., Rohe C.F., Chang H.C., Chen R.S., Weng Y.H., Vanacore N., Breedveld G.J., Oostra B.A., and Bonifati V. A common missense variant in the Lrrk2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7 (2006) 133-138
21. Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L., Fook-Chong S., Tang S., Chua E., Yuen Y., Tan L., Pavanni R., Wong M.C., Kolatkar P., Lu C.S., Bonifati V., and Liu J.J. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum. Genet. 120 (2007) 857-863
22. Funayama M., Li Y., Tomiyama H., Yoshino H., Imamichi Y., Yamamoto M., Murata M., Toda T., Mizuno Y., and Hattori N. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18 (2007) 273-275
23. Li C., Ting Z., Qin X., Ying W., Li B., Guo Q.L., Jian F.M., Jing Z., Jian Q.D., and Sheng D.C. The prevalence of LRRK2 Gly238Arg variant in Chinese Han population with Parkinson's disease. Mov. Disord. 22 (2007) 2439-2443
24. Ross O.A., Wu Y.R., Lee M.C., Funayama M., Chen M.L., Soto A.I., Mata I.F., Lee-Chen G.J., Chen C.M., Tang M., Zhao Y., Hattori N., Farrer M.J., Tan E.K., and Wu R.M. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64 (2008) 88-92
25. Tan E.K., Tan L.C., Lim H.Q., Li R., Tang M., Yih Y., Pavanni R., Prakash K.M., Fook-Chong S., and Zhao Y. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum. Genet. 124 (2008) 287-288